Spontaneous Remission and Concomitant Progression in a Patient with DLBCL

Eun Ji Han,Joo Hyun O,Jihyun Kim,Suk Young Park

doi:10.3390/diagnostics10110950

Eun Ji Han, Joo Hyun O + Show 2 more

Open Access

https://doi.org/10.3390/diagnostics10110950

Copy DOI

Journal: Diagnostics	Publication Date: Nov 14, 2020
Citations: 1	License type: CC BY 4.0

Affiliation: Catholic University of Korea

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. Although DLBCL can be cured in more than half of all patients, up to 50% of patients become refractory to initial treatment or relapse after complete remission. We present a case of complete spontaneous remission of some tumors and concomitant newly developed tumors observed in a patient with relapsed DLBCL. Spontaneous remission of lymphoma without treatment is a rare phenomenon and can occur at baseline as well as in relapsed DLBCL. However, most patients who initially experience spontaneous remission later develop relapse. Thus, careful follow-up is required, and fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) allows monitoring of multiple lesions.

Highlights

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin’s lymphoma (NHL) accounting for approximately 30% of all cases worldwide [1]
The standard first-line treatment for de novo DLBCL is the combination of rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone (R-CHOP) chemotherapy [2]
DLBCL can be cured with first-line chemotherapy in more than half of all patients, up to 50% of patients do not respond to initial treatment or relapse after showing preliminary response [3]

Summary

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin’s lymphoma (NHL) accounting for approximately 30% of all cases worldwide [1]. The standard first-line treatment for de novo DLBCL is the combination of rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone (R-CHOP) chemotherapy [2]. DLBCL can be cured with first-line chemotherapy in more than half of all patients, up to 50% of patients do not respond to initial treatment or relapse after showing preliminary response [3]. Spontaneous remission of lymphoma without treatment is an uncommon phenomenon and is reported with varying range.

Results

Conclusion